

Global Vaccine Particulate Adjuvants Market Growth 2026-2032

<https://marketpublishers.com/r/G15D26798C76EN.html>

Date: May 2026

Pages: 152

Price: US\$ 3,660.00 (Single User License)

ID: G15D26798C76EN

Abstracts

The global Vaccine Particulate Adjuvants market size is predicted to grow from US\$ 1149 million in 2025 to US\$ 1462 million in 2032; it is expected to grow at a CAGR of 3.5% from 2026 to 2032.

Vaccine Particulate Adjuvants are a class of adjuvants or adjuvant systems that exist as particles, colloids, vesicles, complexes, or other discrete micro- and nanostructures and are used to enhance vaccine immunogenicity, improve antigen delivery, and shape the quality of immune responses. They may appear as milky or translucent suspensions, colloidal dispersions, lyophilized powders, wet gels, or reconstituted particulate systems. Structurally, they commonly consist of inorganic salt particles, lipid bilayer vesicles, saponin-lipid complexes, virosomes, polymeric micro- or nanoparticles, or other biomimetic particulate carriers. Typical components include aluminum hydroxide, aluminum phosphate, cholesterol, phospholipids, saponins, monophosphoryl lipid A analogs, biodegradable polymers, and surface-functional excipients. Their mode of action is not limited to simple immune stimulation; rather, they adsorb, entrap, or co-deliver antigens in a particulate form that is more efficiently taken up by antigen-presenting cells. By tuning particle size, surface charge, rigidity, and interfacial chemistry, they promote cell recruitment at the administration site, lymph node trafficking, dendritic cell activation, and coordinated humoral and cellular immunity. Main categories include aluminum-salt particulates, liposomal adjuvants, virosomal adjuvants, ISCOM/ISCOMATRIX-type adjuvants, polymeric particle adjuvants, and other inorganic or biomimetic particulate adjuvants. Their major applications are in recombinant protein vaccines, subunit vaccines, conjugate vaccines, selected inactivated vaccines, therapeutic cancer vaccines, and veterinary vaccines.

Growth opportunities for Vaccine Particulate Adjuvants are primarily driven by changes

in vaccine antigen platforms. Recombinant protein, subunit, conjugate, and many therapeutic vaccines are inherently less immunogenic and therefore more dependent on efficient delivery and immune amplification. Particulate systems are well positioned because they function both as carriers and as immune modulators. Mature aluminum-based systems will continue to provide the bulk of demand, while liposomes, ISCOM/Matrix-M, nano-alum, and polymeric particles are expected to gain share in elderly populations, immunologically weaker populations, and indications requiring stronger Th1 or cellular responses. The real opportunity for suppliers is not merely whether an adjuvant is present, but whether they can build scalable, stable, globally registrable adjuvant platforms compatible with new antigen formats. As RSV, malaria, shingles, broad influenza, therapeutic cancer vaccines, and next-generation veterinary vaccines advance, particulate systems that enable antigen sparing, durable immunity, cold-chain practicality, and differentiated protection profiles should continue to gain commercial importance.

The main restraints in this market are not conceptual novelty but scale-up, raw-material consistency, and regulatory comparability. Particulate adjuvants are highly sensitive to particle-size distribution, surface charge, adsorption capacity, reconstitution behavior, stability windows, and batch-to-batch reproducibility. Once a product moves from laboratory work into commercial manufacturing, the allowable process window narrows sharply. Aluminum salts are mature but offer limited differentiation, whereas liposomal and saponin-complex particles can provide stronger performance but demand tighter control of raw material purity, loading strategy, freeze-thaw stability, analytical methods, and supply-chain security. Critical inputs such as QS-21, MPL-like molecules, specialty lipids, and high-purity phospholipids may also be constrained by plant sourcing, licensing, purification routes, and global production footprint. For investors and industrial analysts, the central risk is to confuse ?works in research? with ?can be manufactured reproducibly at scale,? or to mistake a captive in-house vaccine adjuvant platform for an externally scalable commercial adjuvant business. Competition will therefore increasingly center on CMC, regulatory pathways, intellectual property, and manufacturing scale rather than preclinical efficacy alone.

Downstream demand is showing three clear trends. First, demand is expanding from traditional pediatric immunization into vaccines for older adults, maternal vaccines, cancer immunotherapy, and vaccines for highly pathogenic emerging infections, increasing preference for particulate platforms that can support both antibody and cellular immunity. Second, customers are moving away from simple procurement of standard alum and toward adjuvant-system solutions, meaning they increasingly seek not just a raw material but a combined package of formulation know-how, process

support, analytics, and licensing. Third, veterinary vaccines remain a stable and meaningful demand base, especially in multivalent products, mucosal immunization, and long-duration protection, where polymeric, gel-based, and hybrid particulate systems retain strong relevance. Overall, the market is unlikely to reward the strongest inflammatory signal alone; instead, future purchasing will favor a balanced combination of breadth of protection, tolerability, dose sparing, elderly immune performance, mucosal potential, and global supply reliability.

LP Information, Inc. (LPI) ' newest research report, the ?Vaccine Particulate Adjuvants Industry Forecast? looks at past sales and reviews total world Vaccine Particulate Adjuvants sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaccine Particulate Adjuvants sales for 2026 through 2032. With Vaccine Particulate Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Vaccine Particulate Adjuvants industry.

This Insight Report provides a comprehensive analysis of the global Vaccine Particulate Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccine Particulate Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vaccine Particulate Adjuvants market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine Particulate Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine Particulate Adjuvants.

This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Particulate Adjuvants market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Oral

Subcutaneous

Intranasal

Intramuscular

Intradermal

Others

Segmentation by Particle Architecture:

Mineral gel / precipitated particles

Liposomal vesicles

Virosomal vesicles

Saponin nanoparticle / ISCOM-type complexes

Polymeric micro- or nanoparticles

Others

Segmentation by Material Composition:

Aluminum salt-based particulate adjuvants

Phospholipid-based particulate adjuvants

Saponin-based particulate adjuvants

Polymer-based particulate adjuvants

Virus-membrane / virosome-based particulate adjuvants

Hybrid particulate systems

Others

Segmentation by Antigen Association Mode:

Surface-adsorbed particulate systems

Encapsulated particulate systems

Co-assembled particulate systems

Admixture particulate systems

Others

Segmentation by Application:

Infectious Diseases

Cancer

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

GSK

Merck

Sanofi

Croda

Novavax

SPI Pharma

CSL

Serum Institute of India

Bharat Biotech

Biological E

Panacea Biotec

Valneva

SEPPIC

Phibro Animal Health

Aurorium

Agenus

InvivoGen

OZ Biosciences

Vaxine

Adjuvatis

Desert King

Sinovac

China National Biotec Group

Walvax

Anhui Zhifei Longcom

Key Questions Addressed in this Report

What is the 10-year outlook for the global Vaccine Particulate Adjuvants market?

What factors are driving Vaccine Particulate Adjuvants market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Vaccine Particulate Adjuvants market opportunities vary by end market size?

How does Vaccine Particulate Adjuvants break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Vaccine Particulate Adjuvants Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Vaccine Particulate Adjuvants by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Vaccine Particulate Adjuvants by Country/Region, 2021, 2025 & 2032
- 2.2 Vaccine Particulate Adjuvants Segment by Type
 - 2.2.1 Oral
 - 2.2.2 Subcutaneous
 - 2.2.3 Intranasal
 - 2.2.4 Intramuscular
 - 2.2.5 Intradermal
 - 2.2.6 Others
 - 2.2.7 Vaccine Particulate Adjuvants Sales by Type
 - 2.2.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
 - 2.2.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Type (2021-2026)
 - 2.2.7.3 Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026)
- 2.3 Vaccine Particulate Adjuvants Segment by Particle Architecture
 - 2.3.1 Mineral gel / precipitated particles
 - 2.3.2 Liposomal vesicles
 - 2.3.3 Virosomal vesicles
 - 2.3.4 Saponin nanoparticle / ISCOM-type complexes

2.3.5 Polymeric micro- or nanoparticles

2.3.6 Others

2.3.7 Vaccine Particulate Adjuvants Sales by Particle Architecture

2.3.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)

2.3.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Particle Architecture (2021-2026)

2.3.7.3 Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026)

2.4 Vaccine Particulate Adjuvants Segment by Material Composition

2.4.1 Aluminum salt-based particulate adjuvants

2.4.2 Phospholipid-based particulate adjuvants

2.4.3 Saponin-based particulate adjuvants

2.4.4 Polymer-based particulate adjuvants

2.4.5 Virus-membrane / virosome-based particulate adjuvants

2.4.6 Hybrid particulate systems

2.4.7 Others

2.4.8 Vaccine Particulate Adjuvants Sales by Material Composition

2.4.8.1 Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)

2.4.8.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Material Composition (2021-2026)

2.4.8.3 Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026)

2.5 Vaccine Particulate Adjuvants Segment by Antigen Association Mode

2.5.1 Surface-adsorbed particulate systems

2.5.2 Encapsulated particulate systems

2.5.3 Co-assembled particulate systems

2.5.4 Admixture particulate systems

2.5.5 Others

2.5.6 Vaccine Particulate Adjuvants Sales by Antigen Association Mode

2.5.6.1 Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)

2.5.6.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Antigen Association Mode (2021-2026)

2.5.6.3 Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026)

2.6 Vaccine Particulate Adjuvants Segment by Application

2.6.1 Infectious Diseases

2.6.2 Cancer

2.6.3 Others

2.6.4 Vaccine Particulate Adjuvants Sales by Application

2.6.4.1 Global Vaccine Particulate Adjuvants Sale Market Share by Application
(2021-2026)

2.6.4.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by
Application (2021-2026)

2.6.4.3 Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Vaccine Particulate Adjuvants Breakdown Data by Company

3.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Company (2021-2026)

3.1.2 Global Vaccine Particulate Adjuvants Sales Market Share by Company
(2021-2026)

3.2 Global Vaccine Particulate Adjuvants Annual Revenue by Company (2021-2026)

3.2.1 Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026)

3.2.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Company
(2021-2026)

3.3 Global Vaccine Particulate Adjuvants Sale Price by Company

3.4 Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution,
Sales Area, Product Type

3.4.1 Key Manufacturers Vaccine Particulate Adjuvants Product Location Distribution

3.4.2 Players Vaccine Particulate Adjuvants Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION

4.1 World Historic Vaccine Particulate Adjuvants Market Size by Geographic Region
(2021-2026)

4.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Geographic Region
(2021-2026)

4.1.2 Global Vaccine Particulate Adjuvants Annual Revenue by Geographic Region
(2021-2026)

4.2 World Historic Vaccine Particulate Adjuvants Market Size by Country/Region (2021-2026)

4.2.1 Global Vaccine Particulate Adjuvants Annual Sales by Country/Region (2021-2026)

4.2.2 Global Vaccine Particulate Adjuvants Annual Revenue by Country/Region (2021-2026)

4.3 Americas Vaccine Particulate Adjuvants Sales Growth

4.4 APAC Vaccine Particulate Adjuvants Sales Growth

4.5 Europe Vaccine Particulate Adjuvants Sales Growth

4.6 Middle East & Africa Vaccine Particulate Adjuvants Sales Growth

5 AMERICAS

5.1 Americas Vaccine Particulate Adjuvants Sales by Country

5.1.1 Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026)

5.1.2 Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026)

5.2 Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026)

5.3 Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Vaccine Particulate Adjuvants Sales by Region

6.1.1 APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026)

6.1.2 APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026)

6.2 APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026)

6.3 APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Vaccine Particulate Adjuvants by Country

7.1.1 Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026)

7.1.2 Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026)

7.2 Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026)

7.3 Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vaccine Particulate Adjuvants by Country

8.1.1 Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026)

8.1.2 Middle East & Africa Vaccine Particulate Adjuvants Revenue by Country (2021-2026)

8.2 Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026)

8.3 Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants

10.3 Manufacturing Process Analysis of Vaccine Particulate Adjuvants

10.4 Industry Chain Structure of Vaccine Particulate Adjuvants

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Vaccine Particulate Adjuvants Distributors

11.3 Vaccine Particulate Adjuvants Customer

12 WORLD FORECAST REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION

12.1 Global Vaccine Particulate Adjuvants Market Size Forecast by Region

12.1.1 Global Vaccine Particulate Adjuvants Forecast by Region (2027-2032)

12.1.2 Global Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Vaccine Particulate Adjuvants Forecast by Type (2027-2032)

12.7 Global Vaccine Particulate Adjuvants Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 GSK

13.1.1 GSK Company Information

13.1.2 GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.1.3 GSK Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 GSK Main Business Overview

13.1.5 GSK Latest Developments

13.2 Merck

13.2.1 Merck Company Information

13.2.2 Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.2.3 Merck Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Merck Main Business Overview

13.2.5 Merck Latest Developments

13.3 Sanofi

13.3.1 Sanofi Company Information

13.3.2 Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.3.3 Sanofi Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Sanofi Main Business Overview

13.3.5 Sanofi Latest Developments

13.4 Croda

13.4.1 Croda Company Information

13.4.2 Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.4.3 Croda Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Croda Main Business Overview

13.4.5 Croda Latest Developments

13.5 Novavax

13.5.1 Novavax Company Information

13.5.2 Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.5.3 Novavax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Novavax Main Business Overview

13.5.5 Novavax Latest Developments

13.6 SPI Pharma

13.6.1 SPI Pharma Company Information

13.6.2 SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.6.3 SPI Pharma Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 SPI Pharma Main Business Overview

13.6.5 SPI Pharma Latest Developments

13.7 CSL

13.7.1 CSL Company Information

13.7.2 CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.7.3 CSL Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 CSL Main Business Overview

13.7.5 CSL Latest Developments

13.8 Serum Institute of India

13.8.1 Serum Institute of India Company Information

13.8.2 Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.8.3 Serum Institute of India Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Serum Institute of India Main Business Overview

13.8.5 Serum Institute of India Latest Developments

13.9 Bharat Biotech

13.9.1 Bharat Biotech Company Information

13.9.2 Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.9.3 Bharat Biotech Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Bharat Biotech Main Business Overview

13.9.5 Bharat Biotech Latest Developments

13.10 Biological E

13.10.1 Biological E Company Information

13.10.2 Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.10.3 Biological E Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Biological E Main Business Overview

13.10.5 Biological E Latest Developments

13.11 Panacea Biotec

13.11.1 Panacea Biotec Company Information

13.11.2 Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.11.3 Panacea Biotec Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Panacea Biotec Main Business Overview

13.11.5 Panacea Biotec Latest Developments

13.12 Valneva

13.12.1 Valneva Company Information

13.12.2 Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.12.3 Valneva Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Valneva Main Business Overview

13.12.5 Valneva Latest Developments

13.13 SEPPIC

13.13.1 SEPPIC Company Information

- 13.13.2 SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications
- 13.13.3 SEPPIC Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.13.4 SEPPIC Main Business Overview
- 13.13.5 SEPPIC Latest Developments
- 13.14 Phibro Animal Health
 - 13.14.1 Phibro Animal Health Company Information
 - 13.14.2 Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications
 - 13.14.3 Phibro Animal Health Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Phibro Animal Health Main Business Overview
 - 13.14.5 Phibro Animal Health Latest Developments
- 13.15 Aurorium
 - 13.15.1 Aurorium Company Information
 - 13.15.2 Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications
 - 13.15.3 Aurorium Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.15.4 Aurorium Main Business Overview
 - 13.15.5 Aurorium Latest Developments
- 13.16 Agenesis
 - 13.16.1 Agenesis Company Information
 - 13.16.2 Agenesis Vaccine Particulate Adjuvants Product Portfolios and Specifications
 - 13.16.3 Agenesis Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.16.4 Agenesis Main Business Overview
 - 13.16.5 Agenesis Latest Developments
- 13.17 InvivoGen
 - 13.17.1 InvivoGen Company Information
 - 13.17.2 InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications
 - 13.17.3 InvivoGen Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.17.4 InvivoGen Main Business Overview
 - 13.17.5 InvivoGen Latest Developments
- 13.18 OZ Biosciences
 - 13.18.1 OZ Biosciences Company Information
 - 13.18.2 OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications
 - 13.18.3 OZ Biosciences Vaccine Particulate Adjuvants Sales, Revenue, Price and

Gross Margin (2021-2026)

13.18.4 OZ Biosciences Main Business Overview

13.18.5 OZ Biosciences Latest Developments

13.19 Vaxine

13.19.1 Vaxine Company Information

13.19.2 Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.19.3 Vaxine Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross

Margin (2021-2026)

13.19.4 Vaxine Main Business Overview

13.19.5 Vaxine Latest Developments

13.20 Adjuvatis

13.20.1 Adjuvatis Company Information

13.20.2 Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.20.3 Adjuvatis Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross

Margin (2021-2026)

13.20.4 Adjuvatis Main Business Overview

13.20.5 Adjuvatis Latest Developments

13.21 Desert King

13.21.1 Desert King Company Information

13.21.2 Desert King Vaccine Particulate Adjuvants Product Portfolios and

Specifications

13.21.3 Desert King Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross

Margin (2021-2026)

13.21.4 Desert King Main Business Overview

13.21.5 Desert King Latest Developments

13.22 Sinovac

13.22.1 Sinovac Company Information

13.22.2 Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.22.3 Sinovac Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross

Margin (2021-2026)

13.22.4 Sinovac Main Business Overview

13.22.5 Sinovac Latest Developments

13.23 China National Biotec Group

13.23.1 China National Biotec Group Company Information

13.23.2 China National Biotec Group Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.23.3 China National Biotec Group Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.23.4 China National Biotec Group Main Business Overview

13.23.5 China National Biotec Group Latest Developments

13.24 Walvax

13.24.1 Walvax Company Information

13.24.2 Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.24.3 Walvax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.24.4 Walvax Main Business Overview

13.24.5 Walvax Latest Developments

13.25 Anhui Zhifei Longcom

13.25.1 Anhui Zhifei Longcom Company Information

13.25.2 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications

13.25.3 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)

13.25.4 Anhui Zhifei Longcom Main Business Overview

13.25.5 Anhui Zhifei Longcom Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Vaccine Particulate Adjuvants Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Vaccine Particulate Adjuvants Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Oral

Table 4. Major Players of Subcutaneous

Table 5. Major Players of Intranasal

Table 6. Major Players of Intramuscular

Table 7. Major Players of Intradermal

Table 8. Major Players of Others

Table 9. Global Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)

Table 10. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)

Table 11. Global Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (\$ million)

Table 12. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)

Table 13. Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026) & (US\$/Unit)

Table 14. Major Players of Mineral gel / precipitated particles

Table 15. Major Players of Liposomal vesicles

Table 16. Major Players of Virosomal vesicles

Table 17. Major Players of Saponin nanoparticle / ISCOM-type complexes

Table 18. Major Players of Polymeric micro- or nanoparticles

Table 19. Major Players of Others

Table 20. Global Vaccine Particulate Adjuvants Sales by Particle Architecture (2021-2026) & (K Units)

Table 21. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)

Table 22. Global Vaccine Particulate Adjuvants Revenue by Particle Architecture (2021-2026) & (\$ million)

Table 23. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)

Table 24. Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026) & (US\$/Unit)

Table 25. Major Players of Aluminum salt-based particulate adjuvants
Table 26. Major Players of Phospholipid-based particulate adjuvants
Table 27. Major Players of Saponin-based particulate adjuvants
Table 28. Major Players of Polymer-based particulate adjuvants
Table 29. Major Players of Virus-membrane / virosome-based particulate adjuvants
Table 30. Major Players of Hybrid particulate systems
Table 31. Major Players of Others
Table 32. Global Vaccine Particulate Adjuvants Sales by Material Composition (2021-2026) & (K Units)
Table 33. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)
Table 34. Global Vaccine Particulate Adjuvants Revenue by Material Composition (2021-2026) & (\$ million)
Table 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
Table 36. Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026) & (US\$/Unit)
Table 37. Major Players of Surface-adsorbed particulate systems
Table 38. Major Players of Encapsulated particulate systems
Table 39. Major Players of Co-assembled particulate systems
Table 40. Major Players of Admixture particulate systems
Table 41. Major Players of Others
Table 42. Global Vaccine Particulate Adjuvants Sales by Antigen Association Mode (2021-2026) & (K Units)
Table 43. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)
Table 44. Global Vaccine Particulate Adjuvants Revenue by Antigen Association Mode (2021-2026) & (\$ million)
Table 45. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
Table 46. Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026) & (US\$/Unit)
Table 47. Global Vaccine Particulate Adjuvants Sale by Application (2021-2026) & (K Units)
Table 48. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2021-2026)
Table 49. Global Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (\$ million)
Table 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application

(2021-2026)

Table 51. Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026) & (US\$/Unit)

Table 52. Global Vaccine Particulate Adjuvants Sales by Company (2021-2026) & (K Units)

Table 53. Global Vaccine Particulate Adjuvants Sales Market Share by Company (2021-2026)

Table 54. Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026) & (\$ millions)

Table 55. Global Vaccine Particulate Adjuvants Revenue Market Share by Company (2021-2026)

Table 56. Global Vaccine Particulate Adjuvants Sale Price by Company (2021-2026) & (US\$/Unit)

Table 57. Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution and Sales Area

Table 58. Players Vaccine Particulate Adjuvants Products Offered

Table 59. Vaccine Particulate Adjuvants Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 60. New Products and Potential Entrants

Table 61. Market M&A Activity & Strategy

Table 62. Global Vaccine Particulate Adjuvants Sales by Geographic Region (2021-2026) & (K Units)

Table 63. Global Vaccine Particulate Adjuvants Sales Market Share Geographic Region (2021-2026)

Table 64. Global Vaccine Particulate Adjuvants Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 65. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region (2021-2026)

Table 66. Global Vaccine Particulate Adjuvants Sales by Country/Region (2021-2026) & (K Units)

Table 67. Global Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021-2026)

Table 68. Global Vaccine Particulate Adjuvants Revenue by Country/Region (2021-2026) & (\$ millions)

Table 69. Global Vaccine Particulate Adjuvants Revenue Market Share by Country/Region (2021-2026)

Table 70. Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)

Table 71. Americas Vaccine Particulate Adjuvants Sales Market Share by Country

(2021-2026)

Table 72. Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & (\$ millions)

Table 73. Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)

Table 74. Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)

Table 75. APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (K Units)

Table 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026)

Table 77. APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026) & (\$ millions)

Table 78. APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)

Table 79. APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)

Table 80. Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)

Table 81. Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & (\$ millions)

Table 82. Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)

Table 83. Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)

Table 84. Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)

Table 85. Middle East & Africa Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)

Table 86. Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)

Table 87. Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)

Table 88. Key Market Drivers & Growth Opportunities of Vaccine Particulate Adjuvants

Table 89. Key Market Challenges & Risks of Vaccine Particulate Adjuvants

Table 90. Key Industry Trends of Vaccine Particulate Adjuvants

Table 91. Vaccine Particulate Adjuvants Raw Material

Table 92. Key Suppliers of Raw Materials

Table 93. Vaccine Particulate Adjuvants Distributors List

Table 94. Vaccine Particulate Adjuvants Customer List

Table 95. Global Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032)

& (K Units)

Table 96. Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 97. Americas Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)

Table 98. Americas Vaccine Particulate Adjuvants Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 99. APAC Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032) & (K Units)

Table 100. APAC Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 101. Europe Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)

Table 102. Europe Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 103. Middle East & Africa Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)

Table 104. Middle East & Africa Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 105. Global Vaccine Particulate Adjuvants Sales Forecast by Type (2027-2032) & (K Units)

Table 106. Global Vaccine Particulate Adjuvants Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 107. Global Vaccine Particulate Adjuvants Sales Forecast by Application (2027-2032) & (K Units)

Table 108. Global Vaccine Particulate Adjuvants Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 109. GSK Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 110. GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 111. GSK Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. GSK Main Business

Table 113. GSK Latest Developments

Table 114. Merck Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 115. Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 116. Merck Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Merck Main Business

Table 118. Merck Latest Developments

Table 119. Sanofi Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 120. Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 121. Sanofi Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Sanofi Main Business

Table 123. Sanofi Latest Developments

Table 124. Croda Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 125. Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 126. Croda Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Croda Main Business

Table 128. Croda Latest Developments

Table 129. Novavax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 130. Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 131. Novavax Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Novavax Main Business

Table 133. Novavax Latest Developments

Table 134. SPI Pharma Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 135. SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 136. SPI Pharma Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. SPI Pharma Main Business

Table 138. SPI Pharma Latest Developments

Table 139. CSL Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 140. CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 141. CSL Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 142. CSL Main Business

Table 143. CSL Latest Developments

Table 144. Serum Institute of India Basic Information, Vaccine Particulate Adjuvants

Manufacturing Base, Sales Area and Its Competitors

Table 145. Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 146. Serum Institute of India Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 147. Serum Institute of India Main Business

Table 148. Serum Institute of India Latest Developments

Table 149. Bharat Biotech Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 150. Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 151. Bharat Biotech Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 152. Bharat Biotech Main Business

Table 153. Bharat Biotech Latest Developments

Table 154. Biological E Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 155. Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 156. Biological E Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 157. Biological E Main Business

Table 158. Biological E Latest Developments

Table 159. Panacea Biotec Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 160. Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 161. Panacea Biotec Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 162. Panacea Biotec Main Business

Table 163. Panacea Biotec Latest Developments

Table 164. Valneva Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 165. Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 166. Valneva Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 167. Valneva Main Business

Table 168. Valneva Latest Developments

Table 169. SEPPIC Basic Information, Vaccine Particulate Adjuvants Manufacturing

Base, Sales Area and Its Competitors

Table 170. SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 171. SEPPIC Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 172. SEPPIC Main Business

Table 173. SEPPIC Latest Developments

Table 174. Phibro Animal Health Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 175. Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 176. Phibro Animal Health Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 177. Phibro Animal Health Main Business

Table 178. Phibro Animal Health Latest Developments

Table 179. Aurorium Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 180. Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 181. Aurorium Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 182. Aurorium Main Business

Table 183. Aurorium Latest Developments

Table 184. Agenus Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 185. Agenus Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 186. Agenus Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 187. Agenus Main Business

Table 188. Agenus Latest Developments

Table 189. InvivoGen Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 190. InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 191. InvivoGen Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 192. InvivoGen Main Business

Table 193. InvivoGen Latest Developments

Table 194. OZ Biosciences Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 195. OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 196. OZ Biosciences Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 197. OZ Biosciences Main Business

Table 198. OZ Biosciences Latest Developments

Table 199. Vaxine Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 200. Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 201. Vaxine Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 202. Vaxine Main Business

Table 203. Vaxine Latest Developments

Table 204. Adjuvatis Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 205. Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 206. Adjuvatis Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 207. Adjuvatis Main Business

Table 208. Adjuvatis Latest Developments

Table 209. Desert King Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 210. Desert King Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 211. Desert King Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 212. Desert King Main Business

Table 213. Desert King Latest Developments

Table 214. Sinovac Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 215. Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 216. Sinovac Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 217. Sinovac Main Business

Table 218. Sinovac Latest Developments

Table 219. China National Biotec Group Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 220. China National Biotec Group Vaccine Particulate Adjuvants Product

Portfolios and Specifications

Table 221. China National Biotec Group Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 222. China National Biotec Group Main Business

Table 223. China National Biotec Group Latest Developments

Table 224. Walvax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 225. Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 226. Walvax Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 227. Walvax Main Business

Table 228. Walvax Latest Developments

Table 229. Anhui Zhifei Longcom Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors

Table 230. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications

Table 231. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 232. Anhui Zhifei Longcom Main Business

Table 233. Anhui Zhifei Longcom Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Vaccine Particulate Adjuvants
- Figure 2. Vaccine Particulate Adjuvants Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Vaccine Particulate Adjuvants Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Vaccine Particulate Adjuvants Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Vaccine Particulate Adjuvants Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2025)
- Figure 10. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Oral
- Figure 12. Product Picture of Subcutaneous
- Figure 13. Product Picture of Intranasal
- Figure 14. Product Picture of Intramuscular
- Figure 15. Product Picture of Intradermal
- Figure 16. Product Picture of Others
- Figure 17. Global Vaccine Particulate Adjuvants Sales Market Share by Type in 2026
- Figure 18. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)
- Figure 19. Product Picture of Mineral gel / precipitated particles
- Figure 20. Product Picture of Liposomal vesicles
- Figure 21. Product Picture of Virosomal vesicles
- Figure 22. Product Picture of Saponin nanoparticle / ISCOM-type complexes
- Figure 23. Product Picture of Polymeric micro- or nanoparticles
- Figure 24. Product Picture of Others
- Figure 25. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture in 2026
- Figure 26. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)
- Figure 27. Product Picture of Aluminum salt-based particulate adjuvants
- Figure 28. Product Picture of Phospholipid-based particulate adjuvants
- Figure 29. Product Picture of Saponin-based particulate adjuvants

- Figure 30. Product Picture of Polymer-based particulate adjuvants
- Figure 31. Product Picture of Virus-membrane / virosome-based particulate adjuvants
- Figure 32. Product Picture of Hybrid particulate systems
- Figure 33. Product Picture of Others
- Figure 34. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition in 2026
- Figure 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
- Figure 36. Product Picture of Surface-adsorbed particulate systems
- Figure 37. Product Picture of Encapsulated particulate systems
- Figure 38. Product Picture of Co-assembled particulate systems
- Figure 39. Product Picture of Admixture particulate systems
- Figure 40. Product Picture of Others
- Figure 41. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode in 2026
- Figure 42. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
- Figure 43. Vaccine Particulate Adjuvants Consumed in Infectious Diseases
- Figure 44. Global Vaccine Particulate Adjuvants Market: Infectious Diseases (2021-2026) & (K Units)
- Figure 45. Vaccine Particulate Adjuvants Consumed in Cancer
- Figure 46. Global Vaccine Particulate Adjuvants Market: Cancer (2021-2026) & (K Units)
- Figure 47. Vaccine Particulate Adjuvants Consumed in Others
- Figure 48. Global Vaccine Particulate Adjuvants Market: Others (2021-2026) & (K Units)
- Figure 49. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2025)
- Figure 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application in 2025
- Figure 51. Vaccine Particulate Adjuvants Sales by Company in 2025 (K Units)
- Figure 52. Global Vaccine Particulate Adjuvants Sales Market Share by Company in 2025
- Figure 53. Vaccine Particulate Adjuvants Revenue by Company in 2025 (\$ millions)
- Figure 54. Global Vaccine Particulate Adjuvants Revenue Market Share by Company in 2025
- Figure 55. Global Vaccine Particulate Adjuvants Sales Market Share by Geographic Region (2021-2026)
- Figure 56. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region in 2025

Figure 57. Americas Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)

Figure 58. Americas Vaccine Particulate Adjuvants Revenue 2021-2026 (\$ millions)

Figure 59. APAC Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)

Figure 60. APAC Vaccine Particulate Adjuvants Revenue 2021-2026 (\$ millions)

Figure 61. Europe Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)

Figure 62. Europe Vaccine Particulate Adjuvants Revenue 2021-2026 (\$ millions)

Figure 63. Middle East & Africa Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)

Figure 64. Middle East & Africa Vaccine Particulate Adjuvants Revenue 2021-2026 (\$ millions)

Figure 65. Americas Vaccine Particulate Adjuvants Sales Market Share by Country in 2025

Figure 66. Americas Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)

Figure 67. Americas Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)

Figure 68. Americas Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)

Figure 69. United States Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 70. Canada Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 71. Mexico Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 72. Brazil Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 73. APAC Vaccine Particulate Adjuvants Sales Market Share by Region in 2025

Figure 74. APAC Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2026)

Figure 75. APAC Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)

Figure 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)

Figure 77. China Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 78. Japan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 79. South Korea Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 80. Southeast Asia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 81. India Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 82. Australia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 83. China Taiwan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 84. Europe Vaccine Particulate Adjuvants Sales Market Share by Country in 2025

Figure 85. Europe Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)

Figure 86. Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)

Figure 87. Europe Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)

Figure 88. Germany Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 89. France Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 90. UK Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 91. Italy Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 92. Russia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 93. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026)

Figure 94. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)

Figure 95. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)

Figure 96. Egypt Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 97. South Africa Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 98. Israel Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 99. Turkey Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 100. GCC Countries Vaccine Particulate Adjuvants Revenue Growth 2021-2026 (\$ millions)

Figure 101. Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants in 2026

Figure 102. Manufacturing Process Analysis of Vaccine Particulate Adjuvants

Figure 103. Industry Chain Structure of Vaccine Particulate Adjuvants

Figure 104. Channels of Distribution

Figure 105. Global Vaccine Particulate Adjuvants Sales Market Forecast by Region (2027-2032)

Figure 106. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Region (2027-2032)

Figure 107. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Type (2027-2032)

Figure 108. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Type (2027-2032)

Figure 109. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Application (2027-2032)

Figure 110. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Vaccine Particulate Adjuvants Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G15D26798C76EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G15D26798C76EN.html>